Your browser doesn't support javascript.
loading
Silencing HEATR1 Rescues Cisplatin Resistance of Non-Small Cell Lung Cancer by Inducing Ferroptosis via the p53/SAT1/ALOX15 Axis.
Ma, Xing; Gan, Yifan; Mai, Zhongchao; Song, Yanan; Zhang, Miao; Xia, Wei.
Afiliación
  • Ma X; Department of Nuclear Medicine, Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine.
  • Gan Y; Central Laboratory, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine.
  • Mai Z; Department of Nuclear Medicine, Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine.
  • Song Y; Central Laboratory, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine.
  • Zhang M; Central Laboratory, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine.
  • Xia W; Department of Nuclear Medicine, Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine.
Article en En | MEDLINE | ID: mdl-38818906
ABSTRACT

BACKGROUND:

Cisplatin (DDP) is a commonly used chemotherapy agent. However, its resistance to the drug is a major challenge in its clinical application. Earlier research has suggested a connection between HEATR1 and chemoresistance in cancer. However, additional investigation is needed to better understand its involvement in resistance to DDP. In this study, we aimed to determine the regulatory effect of HEATR1 on the resistance of cisplatin in NSCLC.

METHODS:

We collected specimens of both DDP-resistant and non-resistant NSCLC to examine the expression of HEATR1. Additionally, we established cisplatin-resistant cells of NSCLC using the A549 cell line. Cell ability was examined by CCK-8 assay. Cell apoptosis and lipid ROS were examined by flow cytometry. The expressions of HEATR1, p53, SAT1, and ALOX15 were determined by qRT-PCR and Western blot. The tumor xenograft experiment was conducted to assess the impact of silencing HEATR1 on cisplatin resistance in vivo in NSCLC.

RESULTS:

The expression levels of HEATR1 were found to be significantly elevated in DDP-resistant tissues and cells of NSCLC as compared to non-resistant counterparts. Conversely, the expression levels of p53, SAT1, and ALOX15 were observed to be reduced in DDP-resistant cells. Through the inhibition of HEATR1, the proliferation of DDP-resistant cells was significantly suppressed, while the generation of lipid ROS was enhanced. This effect was achieved by activating ferroptosis and the p53/SAT1/ALOX15 pathway, as demonstrated both in vitro and in vivo. Conversely, the overexpression of HEATR1 exhibited opposite effects. Furthermore, the silencing of p53 and ALOX15 reversed the oncogenic effects of HEATR1 and inhibited ferroptosis in DDP-resistant NSCLC cells, suggesting the involvement of p53 and ALOX15 in HEATR1-mediated DDP resistance.

CONCLUSION:

Finally, the findings revealed that HEATR1 silencing reduced DDP resistance in NSCLC by inducing ferroptosis via the p53/SAT1/ALOX15 axis. HEATR1 might become a potential target for overcoming DDP resistance in NSCLC treatment.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Curr Cancer Drug Targets Asunto de la revista: ANTINEOPLASICOS / NEOPLASIAS Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Curr Cancer Drug Targets Asunto de la revista: ANTINEOPLASICOS / NEOPLASIAS Año: 2024 Tipo del documento: Article